PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Pharmacist-Led Care Halves Time to Antihypertensive Intensification in Older Ethiopian Adults

★ Editor's Pickhypertensiontherapeutic inertiatreatment intensificationpharmacist-led careolder adultsEthiopiaprospective cohort studyantihypertensivesmedication therapy managementambulatory careblood pressure controladherence Ambulatory Care / MTM

Background Information

Pharmacist-led care cuts hypertension treatment time significantly.

Therapeutic inertia in hypertension management increases cardiovascular risk, especially in older adults in low-resource settings. Pharmacist-led care reduced time to treatment intensification to 28 days compared to 63 days in usual care. This study demonstrates that pharmacist interventions can accelerate treatment adjustments and improve hypertension outcomes in resource-limited settings. Applicability may vary due to geographical and systemic differences. Pharmacist-led interventions expedite hypertension treatment adjustments, enhancing blood pressure control.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Dagnew SB, Zerihun TE, Mussie DA, Moges TA, Wondm SA, Bayafers Tamene F, Tarekegn GY, Zewdu WS, Kassaw AT

Citation: Dagnew SB, Zerihun TE, Mussie DA, et al. Improving timeliness of antihypertensive treatment intensification through pharmacist-led interventions among older adult patients in Northwest Ethiopia: Multicenter prospective cohort study. Sage open chronic disease. 2026;17:27558428261452289. doi:10.1177/27558428261452289

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.